Galileo - Biotech Innovation Fund IM/  LU2472219562  /

The objective of the investment policy for the Galileo - Biotech Innovation Fund (the "sub-fund") is to achieve sufficient growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is established, regularly reviewed and adjusted where appropriate by the fund manager exclusively in accordance with the criteria that are defined in the investment objectives / investment policy. The sub-fund is not managed using an index as a benchmark. The sub-fund is an equity fund. The sub-fund invests at least 51% of its net assets in biotech companies. A maximum of 49% of the net sub-fund assets may be invested in liquid assets. In principle, the sub-fund may invest in equities, bonds, money market instruments, certificates, other structured products (e.g. reverse convertible bonds, warrant-linked bonds, convertible bonds), target funds and fixed-term deposits, depending on the market situation and the assessment of the fund management. Such certificates may be based on legally permissible underlying assets such as, e.g., equities, bonds, shares in investment funds, financial indices and foreign exchange. For hedging purposes or to increase the assets, the sub-fund may also use financial instruments whose value depends on the future prices of other assets ("derivatives").

The objective of the investment policy for the Galileo - Biotech Innovation Fund (the "sub-fund") is to achieve sufficient growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is established, regularly reviewed and adjusted where appropriate by the fund manager exclusively in accordance with the criteria that are defined in the investment objectives / investment policy. The sub-fund is not managed using an index as a benchmark.